Healthcare & Pharmaceuticals

India's Panacea Biotec to produce 100 mln Sputnik V doses annually -RDIF

1 minute read

File labelled "Sputnik V coronavirus disease (COVID-19) vaccine", March 24, 2021. REUTERS / Dado Ruvic/File Photo

MOSCOW, April 5 (Reuters) - Indian biotech firm Panacea Biotec Ltd (PNCA.NS) has agreed to produce 100 million doses of Russia's Sputnik V COVID-19 vaccine annually, the Russian Direct Investment Fund (RDIF), which markets the shot internationally, said on Monday.

RDIF did not say when production would begin.

Register now for FREE unlimited access to
Reporting by Vladimir Soldatkin; Writing by Alexander Marrow, ediitng by Emelia Sithole-Matarise

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters